Summary
The move is significant for India’s generic injectable industry, where manufacturing lapses can pose a more immediate risk to patients than defects in medicines taken orally.
New Delhi: India plans to bring all sterile drug products under a central licensing system, tightening oversight of injectables and other medicines, after about 240 injection samples were found to be not of standard quality in fiscal 2026, according to two officials familiar with the matter.